


# PRODUCT INFORMATION



## KPT-276

Item No. 29158

**CAS Registry No.:** 1421919-75-6  
**Formal Name:** (2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]-1-(3,3-difluoro-1-azetidiny)-2-propen-1-one  
**MF:** C<sub>16</sub>H<sub>10</sub>F<sub>8</sub>N<sub>4</sub>O  
**FW:** 426.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 268 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

KPT-276 is supplied as a solid. A stock solution may be made by dissolving the KPT-276 in the solvent of choice, which should be purged with an inert gas. KPT-276 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of KPT-276 in these solvents is approximately 1, 2, and 10 mg/ml, respectively.

KPT-276 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KPT-276 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. KPT-276 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

KPT-276 is an orally bioavailable inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.<sup>1</sup> *In vivo*, KPT-276 (150 mg/kg) increases survival and reduces spleen weight and white blood cell count in an MV4-11 acute myeloid leukemia (AML) mouse xenograft model. It also reduces tumor volume and increases survival in a BT 145 glioblastoma mouse xenograft model when administered at a dose of 75 mg/kg.<sup>2</sup>

### References

1. Ranganathan, P., Yu, X., Na, C., *et al.* Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. *Blood* **120**(9), 1765-1773 (2012).
2. Green, A.L., Ramkissoon, S.H., McCauley, D., *et al.* Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. *Neuro. Oncol.* **17**(5), 697-707 (2015).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM